CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 472 enrolled
Drug / intervention
Otilonium Bromide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04270487
NCT04270487Phase 4Completed
CompareCT.gov

A Randomized Controlled Trial to Evaluate the Short-term Efficacy and Long-term Health Economic Impact of a Dietary Intervention Compared to Pharmacotherapy With a Musculotropic Spasmolytic Agent for Newly Diagnosed or Newly Treated Irritable Bowel Syndrome in Primary Care

Universitaire Ziekenhuizen KU Leuven·interventional·Posted Feb 17, 2020·Updated Nov 17, 2020

In Brief

A Phase 4 clinical trial evaluating IBS Diet and Otilonium Bromide for Irritable Bowel Syndrome. Completed, enrolled 472 participants across 1 site.

Detailed Summary

A randomized controlled trial to evaluate the short-term efficacy and long-term health economic impact of a dietary intervention compared to pharmacotherapy with a musculotropic spasmolytic agent for newly diagnosed or newly treated irritable bowel syndrome in primary care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesBelgium
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedFeb 17, 2020
Enrollment StartJul 26, 2018
Primary CompletionMay 4, 2020
Study CompletionJul 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.4 years ago

Interventions

IBS Dietother

Patients will be randomized to a diet or a mediation treatment

Otilonium Bromidedrug

Patients will be randomized to a diet or a mediation treatment